Items Tagged ‘essential thrombocythemia’

December 20th, 2016

5-Year Survival Improved with Early Use of Jakafi® in Myelofibrosis

By

An analysis of 5-year data from two large clinical trials provide conclusive support that treatment with Jakafi® (ruxolitinib) improves long-term survival, compared to other treatment options for patients with myelofibrosis. Perhaps even more importantly, the data suggests that treatment with Jakafi should be used much earlier in the course of a patient’s disease because it […]

View full entry

Tags: 2016, Acute Myeloid Leukemia, American Society of Hematology, ASH, COMFORT-I, COMFORT-II, essential thrombocythemia, jakafi, MF, mpn, myelofibrosis, myeloproliferative neoplasm


December 16th, 2016

Interferon No Better Than Hydroxyurea and Associated with Worse Side Effects in Polycythemia Vera and Essential Thrombocythemia

By

The use of interferon as initial therapy in MPN is associated with worsening side effects the longer it is used for treatment. These results were recently presented at the 2016 annual meeting of the American Society of Hematology. Myeloproliferative neoplasms (MPNs) are a related group of blood cancers. In these disorders, the bone marrow cells […]

View full entry

Tags: 2016, American Society of Hematology, ASH, essential thrombocythemia, ET, hydroxyurea, Interferon, interferon alpha-2a, MPD-RC 112 trial, mpn, myeloproliferative neoplasms, Myeloproliferative Neoplasms MPN


October 10th, 2016

Myeloproliferative Neoplasms Greatly Affect Patient Quality of Life

By

According to results from the myeloproliferative neoplasms (MPN) Landmark survey, MPN’s negatively affect the quality of life and overall health of patients even a year before their diagnosis. Myeloproliferative neoplasms (MPN) are a related group of blood cancers. In these disorders, the bone marrow cells that produce blood cells develop and function abnormally. The three […]

View full entry

Tags: essential thrombocythemia, ET, mpn, Myeloproliferative Neoplasms MPN, News, PMF, polycythemia vera, primary myelofibrosis, PV


February 10th, 2016

Year in Review: Myeloproliferative Neoplasms

By

Individuals dealing with myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis, typically experience difficult symptoms, life-threatening complications, and are at risk of progression to acute leukemia. The development and approval of the JAK2 inhibitor Jakafi® (Ruxolitinib) has led to more effective management of these symptoms in many patients with PV, positively […]

View full entry

Tags: essential thrombocythemia, jakafi, mpn, myelofibrosis, Myeloproliferative Neoplasms MPN, News, polycythemia vera, research, review


June 18th, 2014

Have a Question about Myeloproliferative Neoplasms? Join us on July 23rd

By

CancerConnect announces the opportunity to engage with a myeloproliferative neoplasm (MPN) expert, on July 23rd, 2014. In this Ask the Expert Series, questions will be answered about polycythemia vera, essential thrombocythemia and myelofibrosis in the MPN Community on CancerConnect. CancerConnect is a safe and private online support community for cancer patients and caregivers. Join the […]

View full entry

Tags: essential thrombocythemia, mpn, myelofibrosis, myeloproliferative neoplasms, Myeloproliferative Neoplasms MPN, News, polycytehmia vera